The firm's EpiSwitch test for blood-based diagnosis of prostate cancer will be evaluated as part of the ongoing PROSTAGRAM trial.
Onkos Molecular Diagnostics is looking for a US partner to commercialize its 11 miRNA-based mir-THYpe test, which it believes offers advantages over tests on the market.
The kit, which was launched today, leverages real-time RT-PCR technology to detect and quantify hepatitis C virus-specific RNA with genotypes 1 to 6.
The firm's new RT-PCR assay identifies 20 gene fusion between NTRK1/2/3 and other genes, allowing clinicians to potentially detect rare forms of different cancers.
The university's researchers have developed a laboratory test that measures the body's response to infection in the blood, and can distinguish between bacterial and viral meningitis.
Designed to run on the company's Sentosa real-time PCR system, the test has been approved for identifying and differentiating Zika in patients.
The multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US, and the firm is also eyeing the Middle East and Africa.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
The firm's Cxbladder Monitor test was shown to have a high negative predictive value compared to other commercially available urine diagnostic tests for bladder cancer.